Etripamil NS

Phase 2

Etripamil NS is one of 3 therapeutic programs targeting Paroxysmal supraventricular tachycardia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Paroxysmal Supraventricular TachycardiaRecruiting

Paroxysmal Supraventricular TachycardiaPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Paroxysmal Supraventricular Tachycardia

#DrugCompanyPhaseTrials

Adenocard

Astellas

Phase 3

1 2

Cardamyst

MMilestone Pharmaceuticals Inc.

Phase 3

6 3

Etripamil NS

MMilestone Pharmaceuticals Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Paroxysmal Supraventricular Tachycardia

NCT05763953

Clinical

Trials by Indication[1]

Paroxysmal supraventricular tachycardia1 trial

The NODE-202 Study Multi-Center, Multi-National, Open-Label, Efficacy and Safety Study of Etripamil Nasal Spray in Pediatric Patients With Paroxysmal Supraventricular Tachycardia

Recruiting·MMilestone Pharmaceuticals Inc.·Phase 2·NCT05763953·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Etripamil NS. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Etripamil NS. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Milestone Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: MMilestone Pharmaceuticals Inc.

Etripamil NS

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Paroxysmal supraventricular tachycardia1 trial

References

Drug Info

Quick Facts

Related News